https://www.wsj.com/articles/a-vaccine-progress-report-11595461075?mod=opinion_lead_pos1
Life probably won’t return to normal until we have a widely distributed Covid-19 vaccine, and the good news is this may happen sooner than expected thanks to years of private investment and new cooperation between the U.S. government and drug companies.
On Wednesday the Trump Administration announced a $1.95 billion advance order for 100 million doses of a promising vaccine candidate by Pfizer and Germany-based BioNTech that could be available by the end of the year. Dare to dream. The drug makers plan to begin the final phase of their clinical trials this month and seek regulatory approval as soon as October.
***
The Administration’s Operation Warp Speed is accelerating vaccine development as well as the manufacturing of ingredients and equipment with the aim of delivering 300 million doses by January 2021. That’s an ambitious target, but the Administration is placing several bets with vaccine makers with the hope that at least one or two will pay off.
Evidence from early-stage clinical trials so far has been promising. Pfizer and BioNTech this month reported preliminary results from 45 volunteers showing that their mRNA vaccine candidate generated levels of neutralizing antibodies 1.8- to 2.8-times higher than those in recovered patients. The vaccine programs cells to produce a viral protein that stimulates an immune response.